Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorpheniramine is a first-generation alkylamine antihistamine primarily used to relieve symptoms of allergic conditions such as allergic rhinitis (hay fever), urticaria (hives), and other skin allergies. It acts as a competitive antagonist at the histamine H1 receptor on target cells in blood vessels and respiratory tract tissues. By blocking H1 receptors, it reduces the effects of endogenous histamine—such as vasodilation and increased capillary permeability—thereby alleviating symptoms like sneezing, runny nose, itching eyes/nose/throat/skin. Chlorpheniramine also has mild anticholinergic properties that can cause side effects such as dry mouth or drowsiness but is considered less sedating than some other first-generation antihistamines. It is available in various formulations including tablets (often as chlorpheniramine maleate), syrups, and injectables[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorpheniramine.